The Regional Biocontainment Laboratory (RBL) at Duke was built with funding from the National Institutes of Health (NIH) to support basic research necessary to develop drugs, diagnostics, and vaccines for emerging infections and biodefense, and to provide surge capacity in the event of a public health emergency. The RBL at Duke was the first of 13 NIH-funded RBLs to open. The RBL at Duke is located on the Duke University Medical Center research campus within the Global Health Research Building (GHRB). As part of the Duke Human Vaccine Institute, the RBL is a state-of-the-art laboratory designed to provide a safe environment for work with hazardous bacteria, fungi, and viruses.
Hazardous microbes are classified in one of four Biosafety Levels (BSL1, BSL2, BSL3, and BSL4). See the FAQs for more details. The RBL was designed for work with BSL2 and BSL3 microbes. No BSL4 work is conducted at Duke University. Research with tuberculosis, plague, tularemia, influenza, cryptococcosis, West Nile Virus, and Yellow Fever is currently in progress in the RBL.
The RBL at Duke was designed to:
The RBL participates in the National Institute of Allergy and Infectious Diseases (NIAID) Biodefense Network, and is prepared to support public health efforts in the event of a biodefense emergency. The NIAID Biodefense Network is comprised of Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases (RCE), as well as National and Regional Biocontainment Laboratories. The RBL contains two Core facilities serving the Southeast Regional Center of Excellence for Emerging Infections and Biodefense (SERCEB). These include the SERCEB BSL3 Aerobiology and Animal Models Core and the SERCEB BSL3 Flow, Biomarkers, and Imaging Core.